Pictet Asset Management Holding SA Decreases Stake in BioCryst Pharmaceuticals, Inc. $BCRX

Pictet Asset Management Holding SA trimmed its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 36.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 471,573 shares of the biotechnology company’s stock after selling 268,937 shares during the period. Pictet Asset Management Holding SA’s holdings in BioCryst Pharmaceuticals were worth $4,459,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of BCRX. Vanguard Group Inc. grew its holdings in shares of BioCryst Pharmaceuticals by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock valued at $173,732,000 after purchasing an additional 482,494 shares in the last quarter. RA Capital Management L.P. purchased a new stake in BioCryst Pharmaceuticals during the fourth quarter valued at $123,452,000. Deerfield Management Company L.P. lifted its position in BioCryst Pharmaceuticals by 159.4% during the third quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock valued at $92,363,000 after purchasing an additional 7,477,000 shares during the last quarter. State Street Corp lifted its position in BioCryst Pharmaceuticals by 12.9% during the fourth quarter. State Street Corp now owns 11,073,211 shares of the biotechnology company’s stock valued at $86,371,000 after purchasing an additional 1,265,773 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its position in BioCryst Pharmaceuticals by 7,807.2% during the fourth quarter. Janus Henderson Group PLC now owns 7,404,386 shares of the biotechnology company’s stock valued at $57,791,000 after purchasing an additional 7,310,745 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Price Performance

NASDAQ BCRX opened at $9.84 on Friday. BioCryst Pharmaceuticals, Inc. has a 52 week low of $6.00 and a 52 week high of $10.94. The firm has a market capitalization of $2.50 billion, a price-to-earnings ratio of -5.53 and a beta of 0.55. The company has a fifty day moving average of $8.96 and a two-hundred day moving average of $8.33.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($3.04). The firm had revenue of $156.41 million during the quarter, compared to analysts’ expectations of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The company’s revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.20 EPS. Equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.63 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on BCRX. Needham & Company LLC reduced their target price on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Cantor Fitzgerald increased their price target on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Tuesday, June 30th. Wall Street Zen lowered BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Wedbush reduced their price objective on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Finally, Citizens Jmp upped their price objective on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a research report on Thursday, May 7th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.67.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.